14 results on '"Panni, Stefano"'
Number of results to display per page
Search Results
2. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial
- Author
-
Friedman, Claire F., D'Souza, Anishka, Bello Roufai, Diana, Tinker, Anna V., de Miguel, Maria, Gambardella, Valentina, Goldman, Jonathan, Loi, Sherene, Melisko, Michelle E., Oaknin, Ana, Spanggaard, Iben, Shapiro, Geoffrey I., ElNaggar, Adam C., Panni, Stefano, Ravichandran, Vignesh, Frazier, Aimee L., DiPrimeo, Daniel, Eli, Lisa D., and Solit, David B.
- Published
- 2024
- Full Text
- View/download PDF
3. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
- Author
-
Bamias, Aristotelis, Davis, Ian D, Galsky, Matthew D, Arranz, José Á, Kikuchi, Eiji, Grande, Enrique, del Muro, Xavier Garcia, Park, Se Hoon, De Giorgi, Ugo, Alekseev, Boris, Mencinger, Marina, Izumi, Kouji, Schutz, Fabio A, Puente, Javier, Li, Jian-Ri, Panni, Stefano, Gumus, Mahmut, Özgüroğlu, Mustafa, Mariathasan, Sanjeev, Poloz, Yekaterina, Bene-Tchaleu, Fabiola, Lee, Chooi, Bernhard, Sandrine, and De Santis, Maria
- Published
- 2024
- Full Text
- View/download PDF
4. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
- Author
-
Rebuzzi, Sara Elena, Signori, Alessio, Banna, Giuseppe Luigi, Gandini, Annalice, Fornarini, Giuseppe, Damassi, Alessandra, Maruzzo, Marco, De Giorgi, Ugo, Basso, Umberto, Chiellino, Silvia, Galli, Luca, Zucali, Paolo Andrea, Fantinel, Emanuela, Naglieri, Emanuele, Procopio, Giuseppe, Milella, Michele, Boccardo, Francesco, Fratino, Lucia, Pipitone, Stefania, Ricotta, Riccardo, Panni, Stefano, Mollica, Veronica, Sorarù, Mariella, Santoni, Matteo, Cortellini, Alessio, Prati, Veronica, Soto Parra, Hector Josè, Santini, Daniele, Atzori, Francesco, Di Napoli, Marilena, Caffo, Orazio, Messina, Marco, Morelli, Franco, Prati, Giuseppe, Nolè, Franco, Vignani, Francesca, Cavo, Alessia, Roviello, Giandomenico, Rescigno, Pasquale, and Buti, Sebastiano
- Published
- 2022
- Full Text
- View/download PDF
5. CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study
- Author
-
Rocca, Andrea, primary, Giudici, Fabiola, additional, Donofrio, Carmine Antonio, additional, Bottin, Cristina, additional, Pinamonti, Maurizio, additional, Ferrari, Benvenuto, additional, Schettini, Francesco, additional, Pineda, Estela, additional, Panni, Stefano, additional, Cominetti, Marika, additional, D’Auria, Patrizia, additional, Bianchini, Simonetta, additional, Varotti, Elena, additional, Ungari, Marco, additional, Ciccarelli, Stefano, additional, Filippini, Marzia, additional, Brenna, Sarah, additional, Fiori, Valentina, additional, Di Mambro, Tomas, additional, Sparti, Angelo, additional, Magnani, Mauro, additional, Zanconati, Fabrizio, additional, Generali, Daniele, additional, and Fioravanti, Antonio, additional
- Published
- 2024
- Full Text
- View/download PDF
6. Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of Meet-URO15 study
- Author
-
Messina, Carlo, primary, Catalano, Martina, additional, roviello, giandomenico, additional, Gandini, Annalice, additional, Maruzzo, Marzo, additional, De Giorgi, Ugo, additional, Pedrazzoli, Paolo, additional, Sbrana, Andrea, additional, Zucali, Paolo Ansrea, additional, Masini, Cristina, additional, Naglieri, Emanuele, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Catalano, Fabio, additional, Fratino, Lucia, additional, Pipitone, Stefania, additional, Ricotta, Riccardo, additional, Panni, Stefano, additional, Mollica, Veronica, additional, Atzori, Francesco, additional, Napoli, Marilena Di, additional, Messina, Marco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Malgeri, Andrea, additional, Tudini, Marianna, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Signori, Alessio, additional, Banna, Giuseppe Luigi, additional, Rescigno, Pasquale, additional, Buti, Stefano, additional, Rebuzzi, Sara Elena, additional, and Fornarini, Giuseppe, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
- Author
-
Bamias, Aristotelis, primary, Davis, Ian D, additional, Galsky, Matthew D, additional, Arranz, José Á, additional, Kikuchi, Eiji, additional, Grande, Enrique, additional, del Muro, Xavier Garcia, additional, Park, Se Hoon, additional, De Giorgi, Ugo, additional, Alekseev, Boris, additional, Mencinger, Marina, additional, Izumi, Kouji, additional, Schutz, Fabio A, additional, Puente, Javier, additional, Li, Jian-Ri, additional, Panni, Stefano, additional, Gumus, Mahmut, additional, Özgüroğlu, Mustafa, additional, Mariathasan, Sanjeev, additional, Poloz, Yekaterina, additional, Bene-Tchaleu, Fabiola, additional, Lee, Chooi, additional, Bernhard, Sandrine, additional, and De Santis, Maria, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
- Author
-
Sobhani, Navid, primary, Bouchè, Victoria, additional, Aldegheri, Giovanni, additional, Rocca, Andrea, additional, D’Angelo, Alberto, additional, Giudici, Fabiola, additional, Bottin, Cristina, additional, Donofrio, Carmine Antonio, additional, Pinamonti, Maurizio, additional, Ferrari, Benvenuto, additional, Panni, Stefano, additional, Cominetti, Marika, additional, Aliaga, Jahard, additional, Ungari, Marco, additional, Fioravanti, Antonio, additional, Zanconati, Fabrizio, additional, and Generali, Daniele, additional
- Published
- 2023
- Full Text
- View/download PDF
9. The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
- Author
-
Rebuzzi, Sara Elena, primary, Signori, Alessio, additional, Stellato, Marco, additional, Santini, Daniele, additional, Maruzzo, Marco, additional, De Giorgi, Ugo, additional, Pedrazzoli, Paolo, additional, Galli, Luca, additional, Zucali, Paolo Andrea, additional, Fantinel, Emanuela, additional, Carella, Claudia, additional, Procopio, Giuseppe, additional, Milella, Michele, additional, Boccardo, Francesco, additional, Fratino, Lucia, additional, Sabbatini, Roberto, additional, Ricotta, Riccardo, additional, Panni, Stefano, additional, Massari, Francesco, additional, Sorarù, Mariella, additional, Santoni, Matteo, additional, Cortellini, Alessio, additional, Prati, Veronica, additional, Soto Parra, Hector Josè, additional, Atzori, Francesco, additional, Di Napoli, Marilena, additional, Caffo, Orazio, additional, Messina, Marco, additional, Morelli, Franco, additional, Prati, Giuseppe, additional, Nolè, Franco, additional, Vignani, Francesca, additional, Cavo, Alessia, additional, Roviello, Giandomenico, additional, Llaja Obispo, Miguel Angel, additional, Porta, Camillo, additional, Buti, Sebastiano, additional, Fornarini, Giuseppe, additional, and Banna, Giuseppe Luigi, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
- Author
-
Basso, Umberto, primary, Paolieri, Federico, additional, Rizzo, Mimma, additional, De Giorgi, Ugo, additional, Bracarda, Sergio, additional, Antonuzzo, Lorenzo, additional, Atzori, Francesco, additional, Cartenì, Giacomo, additional, Procopio, Giuseppe, additional, Fratino, Lucia, additional, D’Arcangelo, Manolo, additional, Fornarini, Giuseppe, additional, Zucali, Paolo, additional, Cusmai, Antonio, additional, Santoni, Matteo, additional, Pipitone, Stefania, additional, Carella, Claudia, additional, Panni, Stefano, additional, Deppieri, Filippo, additional, Zagonel, Vittorina, additional, and Tortora, Giampaolo, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study
- Author
-
Brunelli, Matteo, primary, Martignoni, Guido, additional, Malpeli, Giorgio, additional, Volpe, Alessandro, additional, Cima, Luca, additional, Raspollini, Maria Rosaria, additional, Barbareschi, Mattia, additional, Tafuri, Alessandro, additional, Masi, Giulia, additional, Barzon, Luisa, additional, Ammendola, Serena, additional, Villanova, Manuela, additional, Cerruto, Maria Angela, additional, Milella, Michele, additional, Buti, Sebastiano, additional, Bersanelli, Melissa, additional, Fornarini, Giuseppe, additional, Rebuzzi, Sara Elena, additional, Vellone, Valerio Gaetano, additional, Gaggero, Gabriele, additional, Procopio, Giuseppe, additional, Verzoni, Elena, additional, Bracarda, Sergio, additional, Fanelli, Martina, additional, Sabbatini, Roberto, additional, Passalacqua, Rodolfo, additional, Perrucci, Bruno, additional, Giganti, Maria Olga, additional, Donini, Maddalena, additional, Panni, Stefano, additional, Tucci, Marcello, additional, Prati, Veronica, additional, Ortega, Cinzia, additional, Caliò, Anna, additional, Eccher, Albino, additional, Alongi, Filippo, additional, Pappagallo, Giovanni, additional, Iacovelli, Roberto, additional, Mosca, Alessandra, additional, Umari, Paolo, additional, Montagnani, Ilaria, additional, Gobbo, Stefano, additional, Atzori, Francesco, additional, Munari, Enrico, additional, Maruzzo, Marco, additional, Basso, Umberto, additional, Pierconti, Francesco, additional, Patriarca, Carlo, additional, Colombo, Piergiuseppe, additional, Lapini, Alberto, additional, Conti, Giario, additional, Salvioni, Roberto, additional, Bollito, Enrico, additional, Cossarizza, Andrea, additional, Massari, Francesco, additional, Rizzo, Mimma, additional, Franco, Renato, additional, Zito-Marino, Federica, additional, Aberasturi Plata, Yoseba, additional, Galuppini, Francesca, additional, Sbaraglia, Marta, additional, Fassan, Matteo, additional, Dei Tos, Angelo Paolo, additional, Colecchia, Maurizio, additional, Moch, Holger, additional, Scaltriti, Maurizio, additional, Porta, Camillo, additional, Delahunt, Brett, additional, Giannarini, Gianluca, additional, Bortolus, Roberto, additional, Rescigno, Pasquale, additional, Banna, Giuseppe Luigi, additional, Signori, Alessio, additional, Obispo, Miguel Angel Llaja, additional, Perris, Roberto, additional, and Antonelli, Alessandro, additional
- Published
- 2022
- Full Text
- View/download PDF
12. MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
- Author
-
Brunelli, Matteo, Tafuri, Alessandro, Cima, Luca, Cerruto, Maria Angela, Milella, Michele, Zivi, Andrea, Buti, Sebastiano, Bersanelli, Melissa, Fornarini, Giuseppe, Vellone, Valerio Gaetano, Rebuzzi, Sara Elena, Procopio, Giuseppe, Verzoni, Elena, Bracarda, Sergio, Sabbatini, Roberto, Baldessari, Cinzia, Eccher, Albino, Passalacqua, Rodolfo, Perrucci, Bruno, Giganti, Maria Olga, Donini, Maddalena, Panni, Stefano, Tucci, Marcello, Prati, Veronica, Ortega, Cinzia, Caliò, Anna, Alongi, Filippo, Munari, Enrico, Pappagallo, Giovanni, Iacovelli, Roberto, Mosca, Alessandra, Porta, Camillo, Martignoni, Guido, and Antonelli, Alessandro
- Abstract
AimsAccording to The Cancer Genome Atlas (TCGA), around 9% of bladder carcinomas usually show abnormalities of the murine double minute 2 (MDM2) gene, but a few studies have been investigated them. We profiled MDM2 gene amplification in a series of urothelial carcinomas (UC) considering the molecular subtypes and expression of programmed death ligand 1 (PD-L1).Methods117 patients with muscle-invasive UC (pT2-3) without (N0) or with (N+) lymph-node metastases were revised. Only cases with availability of in toto specimens and follow-up were studied. Tissue microarray was built. p53, ER, RB1, GATA-3, CK20, CK5/6, CD44 and PD-L1 (clone sp263) immunoexpression was evaluated. Fluorescent in situ hybridisation was assessed by using the HER-2/neu, FGFR-3, CDKN2A and MDM2 probes. True (ratio 12q/CEP12 >2) MDM2 gene amplification was distinguished from polyploidy/gains (ratio <2, absolute copy number of MDM-2 >2). MDM2 and PD-L1 values were correlated to the TCGA molecular phenotypes. Statistical analysis was performed.Results6/50 (12%) cases (5 N0 and 1 N+) were amplified for MDM2 without matching to molecular phenotypes. Of 50, 14 (37%) cases expressed PD-L1 at 1% cut-off; 3/50 (9%) at >50% cut-off; of these, 2 cases on side of neoplasia among inflammatory cells. Only one out of six (17%) cases amplified for MDM2 showed expression (>50% cut-off) of PD-L1. MDM2 amplification was independent to all documented profiles (k test=0.3) and was prevalent in recurrent UC.ConclusionMDM2 amplification has been seen in both PD-L1 positive and negative muscle-invasive bladder UC independently from the TCGA molecular phenotypes. MDM2 and PD-L1 might be assessed in order to predict a better response to combo/single targeted therapies.
- Published
- 2022
- Full Text
- View/download PDF
13. Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
- Author
-
Navid Sobhani, Victoria Bouchè, Giovanni Aldegheri, Andrea Rocca, Alberto D’Angelo, Fabiola Giudici, Cristina Bottin, Carmine Antonio Donofrio, Maurizio Pinamonti, Benvenuto Ferrari, Stefano Panni, Marika Cominetti, Jahard Aliaga, Marco Ungari, Antonio Fioravanti, Fabrizio Zanconati, Daniele Generali, Sobhani, Navid, Bouchè, Victoria, Aldegheri, Giovanni, Rocca, Andrea, D’Angelo, Alberto, Giudici, Fabiola, Bottin, Cristina, Donofrio, Carmine Antonio, Pinamonti, Maurizio, Ferrari, Benvenuto, Panni, Stefano, Cominetti, Marika, Aliaga, Jahard, Ungari, Marco, Fioravanti, Antonio, Zanconati, Fabrizio, and Generali, Daniele
- Subjects
PD-L1 ,immune checkpoint inhibitors ,glioblastoma ,Medicine (miscellaneous) ,biomarker ,immune checkpoint inhibitor ,biomarkers ,CD3 ,General Biochemistry, Genetics and Molecular Biology - Abstract
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the glioblastoma multiforme (GBM). Currently, immunotherapies should potentiate the host’s own antitumor immune response against cancer cells, but it has been documented that they are effective only in small subsets of patients. Therefore, accurate predictors of response are urgently needed to identify who will benefit from immune-modulatory therapies. Brain tumors are challenging in terms of treatments. The immune response in the brain is highly regulated, and the immune microenvironment in brain metastases is active with a high density of tumor-infiltrating lymphocytes (TILs, CD3+ T cells) in certain patients and, therefore, may serve as a potential treatment target. In our study, we performed immunohistochemistry for CD3 and PD-L1 along the routine assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status and the IDH1 and 2 status in a single center cohort of 69 patients with GBM (58 primary tumors and 11 recurrences) who underwent standard multimodal therapies (surgery/radiotherapy/adjuvant temozolamide). We analyzed the association of PD-L1 tumor expression and TILs with overall survival (OS). The PD-L1 expression was observed in 25 of 58 (43%) newly diagnosed primary glioblastoma specimens. The sparse-to-moderate density of TILs, identified with CD3+ expression, was found in 48 of 58 (83%) specimens. Neither PD-L1 expression nor TILs were associated with overall survival. In conclusion, TILs and/or PD-L1 expression are detectable in the majority of glioblastoma samples, and even if they slightly relate to the outcome, they do not show a statistically significant correlation.
- Published
- 2023
- Full Text
- View/download PDF
14. Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study
- Author
-
Matteo Brunelli, Guido Martignoni, Giorgio Malpeli, Alessandro Volpe, Luca Cima, Maria Rosaria Raspollini, Mattia Barbareschi, Alessandro Tafuri, Giulia Masi, Luisa Barzon, Serena Ammendola, Manuela Villanova, Maria Angela Cerruto, Michele Milella, Sebastiano Buti, Melissa Bersanelli, Giuseppe Fornarini, Sara Elena Rebuzzi, Valerio Gaetano Vellone, Gabriele Gaggero, Giuseppe Procopio, Elena Verzoni, Sergio Bracarda, Martina Fanelli, Roberto Sabbatini, Rodolfo Passalacqua, Bruno Perrucci, Maria Olga Giganti, Maddalena Donini, Stefano Panni, Marcello Tucci, Veronica Prati, Cinzia Ortega, Anna Caliò, Albino Eccher, Filippo Alongi, Giovanni Pappagallo, Roberto Iacovelli, Alessandra Mosca, Paolo Umari, Ilaria Montagnani, Stefano Gobbo, Francesco Atzori, Enrico Munari, Marco Maruzzo, Umberto Basso, Francesco Pierconti, Carlo Patriarca, Piergiuseppe Colombo, Alberto Lapini, Giario Conti, Roberto Salvioni, Enrico Bollito, Andrea Cossarizza, Francesco Massari, Mimma Rizzo, Renato Franco, Federica Zito-Marino, Yoseba Aberasturi Plata, Francesca Galuppini, Marta Sbaraglia, Matteo Fassan, Angelo Paolo Dei Tos, Maurizio Colecchia, Holger Moch, Maurizio Scaltriti, Camillo Porta, Brett Delahunt, Gianluca Giannarini, Roberto Bortolus, Pasquale Rescigno, Giuseppe Luigi Banna, Alessio Signori, Miguel Angel Llaja Obispo, Roberto Perris, Alessandro Antonelli, Brunelli, Matteo, Martignoni, Guido, Malpeli, Giorgio, Volpe, Alessandro, Cima, Luca, Raspollini, Maria Rosaria, Barbareschi, Mattia, Tafuri, Alessandro, Masi, Giulia, Barzon, Luisa, Ammendola, Serena, Villanova, Manuela, Cerruto, Maria Angela, Milella, Michele, Buti, Sebastiano, Bersanelli, Melissa, Fornarini, Giuseppe, Rebuzzi, Sara Elena, Vellone, Valerio Gaetano, Gaggero, Gabriele, Procopio, Giuseppe, Verzoni, Elena, Bracarda, Sergio, Fanelli, Martina, Sabbatini, Roberto, Passalacqua, Rodolfo, Perrucci, Bruno, Giganti, Maria Olga, Donini, Maddalena, Panni, Stefano, Tucci, Marcello, Prati, Veronica, Ortega, Cinzia, Caliò, Anna, Eccher, Albino, Alongi, Filippo, Pappagallo, Giovanni, Iacovelli, Roberto, Mosca, Alessandra, Umari, Paolo, Montagnani, Ilaria, Gobbo, Stefano, Atzori, Francesco, Munari, Enrico, Maruzzo, Marco, Basso, Umberto, Pierconti, Francesco, Patriarca, Carlo, Colombo, Piergiuseppe, Lapini, Alberto, Conti, Giario, Salvioni, Roberto, Bollito, Enrico, Cossarizza, Andrea, Massari, Francesco, Rizzo, Mimma, Franco, Renato, Zito-Marino, Federica, Aberasturi Plata, Yoseba, Galuppini, Francesca, Sbaraglia, Marta, Fassan, Matteo, Dei Tos, Angelo Paolo, Colecchia, Maurizio, Moch, Holger, Scaltriti, Maurizio, Porta, Camillo, Delahunt, Brett, Giannarini, Gianluca, Bortolus, Roberto, Rescigno, Pasquale, Banna, Giuseppe Luigi, Signori, Alessio, Obispo, Miguel Angel Llaja, Perris, Roberto, Antonelli, Alessandro, Brunelli M., Martignoni G., Malpeli G., Volpe A., Cima L., Raspollini M.R., Barbareschi M., Tafuri A., Masi G., Barzon L., Ammendola S., Villanova M., Cerruto M.A., Milella M., Buti S., Bersanelli M., Fornarini G., Rebuzzi S.E., Vellone V.G., Gaggero G., Procopio G., Verzoni E., Bracarda S., Fanelli M., Sabbatini R., Passalacqua R., Perrucci B., Giganti M.O., Donini M., Panni S., Tucci M., Prati V., Ortega C., Calio A., Eccher A., Alongi F., Pappagallo G., Iacovelli R., Mosca A., Umari P., Montagnani I., Gobbo S., Atzori F., Munari E., Maruzzo M., Basso U., Pierconti F., Patriarca C., Colombo P., Lapini A., Conti G., Salvioni R., Bollito E., Cossarizza A., Massari F., Rizzo M., Franco R., Zito-Marino F., Plata Y.A., Galuppini F., Sbaraglia M., Fassan M., Dei Tos A.P., Colecchia M., Moch H., Scaltriti M., Porta C., Delahunt B., Giannarini G., Bortolus R., Rescigno P., Banna G.L., Signori A., Obispo M.A.L., Perris R., and Antonelli A.
- Subjects
angiogenesis ,clear cell renal cell carcinoma ,tumor sampling ,intratumoral heterogeneity ,immunity ,immunohistochemistry ,Medicine (miscellaneous) ,angiogenesi - Abstract
We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole tumor was sampled, and 0.6 mm cores were taken from each block to construct a tissue microarray; third, the residual tissue, mapped by taking pieces 0.5 × 0.5 cm, reconstructed the entire tumor mass. Precisely, six randomly derived pieces of tissues were placed in each cassette, with the number of cassettes being based on the diameter of the tumor (called multisite 3D fusion). Angiogenic and immune markers were tested. Routine 5231 tissue blocks were obtained. Multisite 3D fusion sections showed pattern A, homogeneous high vascular density (10%), pattern B, homogeneous low vascular density (8%) and pattern C, heterogeneous angiogenic signatures (82%). PD-L1 expression was seen as diffuse (7%), low (33%) and absent (60%). Tumor-infiltrating CD8 scored high in 25% (pattern hot), low in 65% (pattern weak) and zero in 10% of cases (pattern desert). Grading was upgraded in 26% of cases (G3–G4), necrosis and sarcomatoid/rhabdoid characters were observed in, respectively, 11 and 7% of cases after 3D fusion (p = 0.03). CD8 and PD-L1 immune expressions were higher in the undifferentiated G4/rhabdoid/sarcomatoid clearRCC subtypes (p = 0.03). Again, 22% of cases were set to intermediate to high risk of clinical recurrence due to new morphological findings of all aggressive G4, sarcomatoid/rhabdoid features by using 3D fusion compared to standard methods (p = 0.04). In conclusion, we propose an easy-to-apply multisite 3D fusion sampling that negates bias due to tumor heterogeneity.
- Published
- 2022
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.